Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Captain Wild Bill Wichrowski has been open with Deadliest Catch fans about his cancer battle. Here's the latest update.

Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...

With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...